The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
Take the type 1 diabetes (T1D) space, as one example. Today, new and exciting advancements are working to reduce barriers, ...
This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.
Introduction The U.S. Food and Drug Administration (FDA) has granted approval for Sanofi’s (NASDAQ:SNY) hemophilia therapy, Qfitlia, marking a significant advancement in treatment options for patients ...
Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...
The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older ...
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback